An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension

Status:	Completed
Conditions:	High Blood Pressure (Hypertension)
Therapuetic Areas:	Cardiology / Vascular Diseases
Healthy:	No
Age Range:	18 - Any
Updated:	4/21/2016
Start Date:	January 2011
End Date:	December 2011

A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg After 8 Week Treatment in Patients With Mild-to-moderate Systolic Hypertension

The purpose of the study is to evaluate dose response of blood pressure lowering for 4 doses
of AHU377, given once daily (50 mg, 100 mg, 200 mg and 400 mg) in combination with a fixed
dose of valsartan (320 mg).

Inclusion Criteria:

- Written informed consent must be obtained before any assessment is performed.
Patients with mild-to-moderate systolic hypertension, untreated or currently taking
antihypertensive therapy.

- Ability to communicate and comply with all study requirements and demonstrate good
medication compliance (≥ 80% compliance rate) during the run-in period.

Exclusion Criteria:

- Severe hypertension

- History of angioedema, drug-related or otherwise, as reported by the patient.

- Pregnant or nursing (lactating) women.

- Women of child-bearing potential (WOCBP), UNLESS they are using adequate birth
control methods.

- History or evidence of a secondary form of hypertension.

- Other protocol-defined inclusion/exclusion criteria may apply

We found this trial at

sites

Novartis Investigative Site

Buffalo, New York 14215

from

Buffalo, NY